The results revealed that in patients with HER2 over-expressing breast cancer, a positive correlation was observed between ERCC1 expression and TIDE score (Figure 3E), suggesting that ERCC1 expression could impact the effects of immunotherapy. The gene discussed is ERCC1; the disease is breast carcinoma.